Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.49 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | KDM4B | O94953 | 1/20 | 0.43 |
| ▸ | KDM5C | P41229 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 8/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034928 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1LMNATSHRADORA2A | |
| SCHEMBL6641800 | 0.71 | TDP1 (0.38) | SMN1; SMN2ALDH1A1LMNATSHRADORA2A | |
| SCHEMBL12005970 | 0.71 | LMNA (0.41) | SMN1; SMN2ALDH1A1LMNATSHRADORA2A | |
| SCHEMBL9127861 | 0.69 | — | — | |
| SCHEMBL1415174 | 0.68 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1KDM4AKDM4BKDM5C | |
| SCHEMBL7536489 | 0.68 | HTT (0.38) | SMN1; SMN2LMNATSHRADORA2ASLC6A4 | |
| Hypoxanthine SCHEMBL30096461 | 0.67 | ALDH1A1 (1.00) | SMN1; SMN2ALDH1A1LMNATSHRADORA2A | |
| Hypoxanthine SCHEMBL7037918 | 0.67 | ALDH1A1 (1.00) | SMN1; SMN2ALDH1A1LMNATSHRADORA2A | |
| Hypoxanthine SCHEMBL25381 | 0.67 | ALDH1A1 (1.00) | SMN1; SMN2ALDH1A1LMNATSHRADORA2A | |
| Allopurinol SCHEMBL4628 | 0.67 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1LMNATSHRADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| WO-2024226914-A2 | MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF | SEPTERNA, INC. (US) | 2024-10-31 | — | — | WO | claimed |
| WO-2017064068-A1 | NEW TRPA1 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2017-04-20 | — | — | WO | claimed |
| WO-2017060488-A1 | NEW TRPA1 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2017-04-13 | — | — | WO | claimed |
| EP-3099689-A1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2016-12-07 | — | — | EP | claimed |
| WO-2015114647-A1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-08-06 | — | — | WO | claimed |
| WO-2014024125-A1 | PYRAZOLO[4,3-D]PYRIMIDIN-7(6H)-ONE DERIVATIVES AS PDE9 INHIBITORS | CELON PHARMA S.A. (PL) | 2014-02-13 | — | — | WO | claimed |
| WO-2008071650-A2 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-19 | — | — | WO | claimed |
| EP-1315729-B1 | COMPOUNDS IN THE FORM OF HOMODIMERIC OR HETERODIMERIC PRODRUGS; PROCESS FOR OBTAINING THESE PRODRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASES-MEDIATED DISEASES OR DYSFUNCTION | CRISTALIA PROD QUIMICOS FARM (BR) | 2008-01-09 | — | — | EP | claimed |
| US-7148350-B2 | Compounds in the form of homodimeric or heterodimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterases-mediated diseases or dysfunction | CRISTALIA PROD.QUI.FARM. LTDA (BR) | 2006-12-12 | — | — | US | claimed |
| EP-1315729-A4 | COMPOUNDS IN THE FORM OF HOMODIMERIC, HETERODIMERIC AND/OR HOMO AND HETEROMULTIMERIC PRO-DRUGS; PROCESS FOR OBTAINING THESE PRO-DRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASIS-MEDIATED DISEASES OR DYSFUNCTION | CRISTALIA PRODUTOS QUIMICOS E (BR) | 2004-07-07 | — | — | EP | claimed |
| US-20040106629-A1 | Compouds in the form of homodimeric, heterodimeric and/or homo and heteromultimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterasis-mediated deseases or dysfunction | PACHECO, OGARI (BR) | 2004-06-03 | — | — | US | claimed |
| EP-1315729-A1 | COMPOUNDS IN THE FORM OF HOMODIMERIC, HETERODIMERIC AND/OR HOMO AND HETEROMULTIMERIC PRO-DRUGS; PROCESS FOR OBTAINING THESE PRO-DRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASIS-MEDIATED DISEASES OR DYSFUNCTION | Cristalia Produtos Quimicos e Farmaceuticos Ltda (BR) | 2003-06-04 | — | — | EP | claimed |
| EP-1296982-A1 | 1-(HETEROARYL-PHENYL)-CONDENSED PYRAZOL DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-04-02 | — | — | EP | claimed |
| WO-2002012241-A1 | COMPOUNDS IN THE FORM OF HOMODIMERIC, HETERODIMERIC AND/OR HOMO AND HETEROMULTIMERIC PRO-DRUGS; PROCESS FOR OBTAINING THESE PRO-DRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASIS-MEDIATED DISEASES OR DYSFUNCTION | Cristália Produtos Químicos e Farmacêuticos Ltda. (BR) | 2002-02-14 | — | — | WO | claimed |
| WO-2002000655-A1 | 1 - (HETEROARYL-PHENYL) - CONDENSED PYRAZOL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-03 | — | — | WO | claimed |
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2026-05-14 | — | — | US | disclosed |
| US-12617799-B2 | Pyrazolopyrimidinone compounds | Orphagen Pharmaceuticals, Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-0201188-A2 | 5-Substituted pyrazolo[4,3-d] pyrimidine-7-ones, process for preparing the compounds and pharmaceutical compositions comprising the compounds | WARNER-LAMBERT COMPANY (US) | 1986-12-17 | — | — | EP | disclosed |
| US-4469868-A | ANTIPSYCHOTIC ANGENTS | WARNER-LAMBERT COMPANY (US) | 1984-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | F11, F13B, F7 | SMN1; SMN2 2158/4885ALDH1A1 2202/4885LMNA 212/4885 |
| US-20040106629-A1 | Compouds in the form of homodimeric, heterodimeric and/or homo and heteromultimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterasis-mediated deseases or dysfunction | PEPD, PREP, PAPSS1 | SMN1; SMN2 1957/4885ALDH1A1 2739/4885LMNA 369/4885 |
| US-12617799-B2 | Pyrazolopyrimidinone compounds | CYP2B6, CBR1, CYP2D6 | SMN1; SMN2 3174/4885ALDH1A1 975/4885LMNA 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.